With dostarlimab, pembrolizumab, and durvalumab showing similar efficacy in endometrial cancer, the final selection often depends on non-clinical factors like clinician familiarity, specific trial criteria, or insurance company mandates.
While immunotherapy is transformational for DMMR endometrial cancer, its benefit is much smaller for the PMMR majority (two-thirds of patients). This reality requires more nuanced patient counseling and selective use in this population.
Depression is highly prevalent in the advanced endometrial cancer population, affecting up to 50% of patients. It is often missed by clinicians and unreported by patients, despite its significant impact on treatment adherence and mortality.
The rationale for adding PARP inhibitors to immunotherapy in endometrial cancer is to induce DNA damage and cell death. This process creates neoantigens, potentially making tumors more recognizable and vulnerable to the immune system, especially in PMMR patients.
Clinicians can differentiate side effects based on their profile: "-itis" symptoms (colitis, pneumonitis) suggest immunotherapy, while cytopenias and neuropathy point to chemotherapy. Response to steroids is a key diagnostic clue for immune-related events.
For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.
Not all institutions automatically run crucial biomarker tests like MMR or p53. Oncology nurses play a critical quality assurance role by checking pathology reports and prompting providers to ensure this essential testing is completed.
A majority of patients on the lenvatinib/pembrolizumab regimen require dose reductions due to toxicity. Crucially, clinical trial data shows no significant change in progression-free survival for patients on lower doses, an important point for patient reassurance.
The four TCGA molecular profiles (e.g., POLE-mutated, p53-abnormal) have evolved beyond predicting outcomes to actively guiding treatment, such as de-escalating therapy for low-risk groups and escalating for high-risk ones.
While most MMR-deficient patients don't have Lynch syndrome, the biomarker is a crucial screening tool for this hereditary cancer condition. This finding has significant implications for both the patient and their family's health through cascade genetic testing.
Unlike chemotherapy, immune-related adverse events have a delayed onset. Nurses must educate patients that toxicities can appear long after treatment initiation and even after its conclusion, requiring long-term vigilance.
Optimal care involves introducing palliative services early—within eight weeks of diagnosis for advanced or recurrent endometrial cancer. This proactive approach focuses on symptom management and quality of life, not just end-of-life care, and can improve outcomes.